

ESMO Advanced Course on Precision Oncology in Breast Cancer

PROGRAMME

**ESMO ADVANCED
COURSE**

**BARCELONA SPAIN
9-10 JUNE 2023**

Co-Chairs

Ana Bosch, Sweden

Giuseppe Curigliano, Italy

ESMO ADVANCED COURSE PROGRAMME PRECISION ONCOLOGY IN BREAST CANCER

Barcelona, Spain
9-10 June 2023

CO-CHAIRS Ana Bosch, Sweden
Giuseppe Curigliano, Italy

SPEAKERS Judith Balmaña, Spain
Javier Cortés, Spain
Mafalda Oliveira, Spain
Barbara Pistilli, France
Aleix Prat, Spain
Giancarlo Pruneri, Italy
Cristina Saura, Spain
Dario Trapani, Italy
Nicholas Turner, United Kingdom

LEARNING OBJECTIVES

- To understand the function and biology of the most relevant driver molecular alterations in early and metastatic breast cancer
- To gain insights in the spectrum of breast cancer molecular aberrations, platforms, and strategies for molecular testing
- To provide information and in-depth discussion on the state-of-the-art and emerging therapeutic strategies integrating major germinal or somatic mutations, driving oncogene addiction in early and metastatic breast cancer
- To present novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies for metastatic breast cancer

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

The Lilly logo is written in a red, cursive script font.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 9 June 2023

- 09:00-09:10** **Welcome and introduction**
- 10' Welcome and learning objectives introduction
Ana Bosch, SE and Giuseppe Curigliano, IT
- 09:10-10:35** **Session 1 – Molecular targets in ER+ disease – ESR1 mutations**
Chair: Giuseppe Curigliano, IT
- 15' ER – Biology of the target / biomarker
Nicholas Turner, UK
- 15' Update on the clinical efficacy of targeted agents: Indications, efficacy and toxicity
Giuseppe Curigliano, IT
- 15' ESR1 mutations – Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Nicholas Turner, UK
- 10' Q&A
- 15' A clinicopathological case presented and discussed by a Molecular Tumour Board
Giuseppe Curigliano, IT
- 15' Q&A and Chair conclusion
- 10:35-11:05** **Coffee break**
- 11:05-12:45** **Session 2 – Molecular targets in ER+ disease – PIK3CA and AKT pathway**
Chair: Ana Bosch, SE
- 30' The PI3K Pathway – Insights into the biology and clinical research
Ana Bosch, SE
- 15' Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Mafalda Oliveira, ES
- 10' Q&A
- 15' A clinicopathological case presented and discussed by a Molecular Tumour Board
Mafalda Oliveira, ES
- 10' Q&A
- 15' Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD) for ESR1, PIK3CA and AKT
Dario Trapani, IT
- 5' Chair conclusion
- 12:45-13:45** **Lunch**
- 13:45-15:25** **Session 3 – Molecular targets in TNBC disease – TILs, PDL1 and Ki 67**
Chair: Giancarlo Pruneri, IT
- 20' Biology of the target / biomarker
Giancarlo Pruneri, IT
- 20' Update on the clinical efficacy of targeted agents: Indications, efficacy and toxicity
Barbara Pistilli, FR
- 20' Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Giancarlo Pruneri, IT
- 10' Q&A
- 15' A clinicopathological case presented and discussed by a Molecular Tumour Board
Barbara Pistilli, FR
- 15' Q&A and Chair conclusion
- 15:25-15:55** **Coffee break**

15:55-17:40	Session 4 – Molecular targets in TNBC disease – BRCA/PALB2 germinal and somatic mutations Chair: Giuseppe Curigliano, IT
30'	Biology and testing of biomarkers for targeted therapy in TNBC Judith Balmaña, ES
15'	Update on the clinical efficacy of targeted agents: Indications, efficacy and toxicity Cristina Saura, ES
10'	Q&A
15'	A clinicopathological case presented and discussed by a Molecular Tumour Board Cristina Saura, ES
10'	Q&A
20'	Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD) for PDL1, BRCA, Ki67 and TILs Dario Trapani, IT
5'	Chair conclusion
19:30	<i>Networking Dinner</i>

Saturday, 10 June 2023

09:00-10:50	Session 5 – HER2 as a target in breast cancer Chair: Giuseppe Curigliano, IT
20'	Update on the clinical treatment algorithm in HER2 positive disease (early and metastatic) Javier Cortés, ES
20'	HER2 pathway: Testing HER2 expression and HER2 mutations Aleix Prat, ES
20'	HER2 low disease – Clinical trials and challenges in testing Giuseppe Curigliano, IT
20'	Q&A
15'	Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD) Dario Trapani, IT
15'	Q&A and Chair conclusion
10:50-11:20	<i>Coffee break</i>
11:20-12:15	Session 6 – Genomics in breast cancer management Chair: Ana Bosch, SE
15'	Role of genomic assays in early breast cancer Aleix Prat, ES
15'	Integrating NGS in treatment selection for metastatic breast cancer (solid biopsy vs ctDNA) Mafalda Oliveira, ES
15'	Role of genomic assays in metastatic setting: A focus on immunotherapy Giuseppe Curigliano, IT
10'	Q&A
12:15-12:30	Synthesis and wrap-up
12:30-13:30	<i>Lunch</i>